Sugi Predict

Sugi Predict / Compounds / SCHEMBL15055587

SCHEMBL15055587

SCHEMBL15055587

COC(=O)c1ccc(NS(=O)(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2)cc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PFKFB3 Q16875 5/20 0.51
▸ PLAU P00749 6/20 0.50
▸ PLAT P00750 2/20 0.50
▸ PTGES2 Q9H7Z7 2/20 0.47
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ HDAC9 Q9UKV0 1/20 0.46
▸ HDAC5 Q9UQL6 1/20 0.46
▸ HSD17B2 P37059 1/20 0.46
▸ MCL1 Q07820 1/20 0.46
▸ KIF11 P52732 1/20 0.46
▸ KIT P10721 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9996947 0.91 PFKFB3 (0.61) PFKFB3PTGES2HDAC3HDAC4HDAC1
SCHEMBL15056302 0.89 ERAP1 (0.56) PFKFB3PLAUPLATPTGES2HSD17B2
SCHEMBL15055200 0.89 HDAC3 (0.58) PFKFB3PTGES2HDAC3HDAC4HDAC1
SCHEMBL15056189 0.87 PFKFB3 (0.57) PFKFB3PLAUPLATHSD17B2MCL1
SCHEMBL15055770 0.84 PFKFB3 (0.54) PFKFB3PLAUPLATHSD17B2MCL1
SCHEMBL15056266 0.84 PFKFB3 (0.51) PFKFB3PLAUPLATPTGES2
SCHEMBL15055263 0.84 ALDH1A1 (0.51) PFKFB3PLAUPLATHSD17B2MCL1
Trifluoroacetic Acid SCHEMBL16393874 0.83 PFKFB3 (0.52) PFKFB3PLAUPLATHSD17B2MCL1
SCHEMBL16408031 0.83 PFKFB3 (0.55) PFKFB3PLAUPLATHSD17B2MCL1
Trifluoroacetic Acid SCHEMBL15055923 0.82 PFKFB3 (0.51) PFKFB3PLAUPLATHSD17B2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US claimed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 — — CN claimed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 — — US claimed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 — — EP claimed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 — — US claimed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 — — US claimed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 — — US claimed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 — — EP claimed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 — — WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 — — CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 — — WO disclosed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 — — US disclosed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 — — US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 — — US disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 — — US disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 — — US disclosed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 — — EP disclosed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 — — WO disclosed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF PFKFB3 909/4885PLAU 3244/4885PLAT 4072/4885
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF PFKFB3 988/4885PLAU 3247/4885PLAT 4050/4885
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885PLAU 2025/4885PLAT 2336/4885
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer NFKBIA, IL6, LITAF PFKFB3 988/4885PLAU 3247/4885PLAT 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.